AstraZeneca has agreed to buy the rights to respiratory drugs owned by Almirall for $2.1 billion, with Covington & Burling and British firm CMS Cameron McKenna. Meanwhile, Kirkland & Ellis and Sidley Austin are leading the way on Pfizer's acquisition of Baxter International's vaccine portfolio.
July 30, 2014 at 08:07 PM
1 minute read
AstraZeneca PLC, the second-largest drugmaker in the U.K., said on Wednesday that it would pay up to $2.1 billion in cash and debt to buy the rights to respiratory drugs owned by Spanish group Almirall.
As part of the deal, AstraZeneca will pay an initial $875 million for the respiratory drugs and an additional $1.22 billion if the drugs meet certain development and sales goals. The deal is subject to regulatory approval and is expected to be completed by the end of 2014.
Presented by BigVoodoo
Join General Counsel and Senior Legal Leaders at the Premier Forum Designed For and by General Counsel from Fortune 1000 Companies
Join General Counsel and Senior Legal Leaders at the Premier Forum Designed For and by General Counsel from Fortune 1000 Companies
Honoring outstanding legal achievements focused at the national level, largely around Big Law and in-house departments.
Duane Morris LLP seeks a highly motivated junior associate to join its dynamic and growing Labor and Employment Class Action group in Chicag...
Duane Morris LLP seeks a full-time staff litigation attorney who has practiced between 3-5 years. Experience will include drafting motions, ...
Duane Morris LLP has an immediate opening for a senior level, highly motivated litigation associate to join its dynamic and growing Employme...
MELICK & PORTER, LLP PROMOTES CONNECTICUT PARTNERS HOLLY ROGERS, STEVEN BANKS, and ALEXANDER AHRENS
The American Lawyer provides the most informed and trusted source of news, data, analysis and forecasting on the global business of law.
